Company intelligence / Profile preview
Shanghai HyaMab Biotechnology
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
HyaMab has advanced its lead program HY‑0102 into Phase 1 trials in patients with advanced/metastatic solid tumors. Preliminary data from a first-in-human trial of PE0116 showed durable responses in late-stage solid tumor patients with ongoing dose escalation. The company’s pipeline includes both clinical-stage and discovery/preclinical assets targeting novel mechanisms in immuno-oncology.
- Therapeutic areas
- OncologyHematology
- Modalities
- monoclonal antibodies (mAbs)allogenic NK cellsCAR-engineered NK/T cellscell therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Tianjin University XinCheng Hospital—strategic cooperation on NK cell therapies including CAR-NK technologiesCollaborations with international research labs such as Intelligent Medicine and SIAIS/ShanghaiTech UniversityClinical trial partnership with Shanghai YingLi Pharmaceutical Co., Ltd. for combination studies involving HY‑0102
Beyond the preview
Go deeper on Shanghai HyaMab Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai HyaMab Biotechnology.